Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Induction Immunotherapy to Promote Immunologic Priming and Enhanced Response to Neoadjuvant Pembrolizumab + Chemotherapy in Triple Negative Breast Cancer (TNBC)

Next Previous
Search
Trial Profile

Induction Immunotherapy to Promote Immunologic Priming and Enhanced Response to Neoadjuvant Pembrolizumab + Chemotherapy in Triple Negative Breast Cancer (TNBC)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IRX 2 (Primary) ; Pembrolizumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Advanced breast cancer; Early breast cancer; Male breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms NeoIRX

Most Recent Events

  • 06 Jun 2023 Status changed to discontinued, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 06 Jun 2023 Results assessing preliminary outcomes of pembrolizumab in stage II/III triple-negative breast cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 23 Mar 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top